For instance, a recent study demonstrated that a chimeric antibody targeting TRIM14 (called Chanti-TRIM) can successfully inhibit cell growth migration and invasion of osteosarcoma cells by inhibiting the MMP-induced NF-κB signalling pathway and chemosensitize osteosarcoma cells to cisplatin treatment by promoting apoptosis possibly by regulating the NF-κB signal pathway [114]. The gene discussed is NFKB1; the disease is osteosarcoma.